Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial

References

• Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117(4):429–441. doi:10.1016/S0002-9394(14)70001-7
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116(1):87–93. doi:10.1016/j.ophtha.2008.09.034
   PubMed Web of Science ®Google Scholar
• Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90(2):e98–e103. doi:10.1111/j.1755-3768.2011.02292.x
   PubMed Web of Science ®Google Scholar
• Qian T, Zhao M, Wan Y, Li M, Xu X. Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion. BMJ Open. 2018;8(12):e022700. doi:10.1136/bmjopen-2018-022700
   PubMed Web of Science ®Google Scholar
• Scott IU, VanVeldhuisen PC, Ip MS, et al.; SCORE2 Investigator Group. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA. 2017;317(20):2072–2087. doi:10.1001/jama.2017.4568
   PubMed Web of Science ®Google Scholar
• Lotfy A, Solaiman KAM, Abdelrahman A, Samir A. Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2018;38(9):1795–1800. doi:10.1097/IAE.0000000000001782
   PubMed Web of Science ®Google Scholar
• Hykin P, Prevost AT, Vasconcelos JC, et al.; LEAVO Study Group. Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol. 2019;137(11):1256–1264. doi:10.1001/jamaophthalmol.2019.3305
   PubMed Web of Science ®Google Scholar
• Rhoades W, Dickson D, Nguyen QD, Do DV. Management of macular edema due to central retinal vein occlusion - The role of aflibercept. Taiwan J Ophthalmol. 2017;7(2):70–76. doi:10.4103/tjo.tjo_9_17
   PubMedGoogle Scholar
• Chung C, Pherwani N. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Am J Health Syst Pharm. 2013;70(21):1887–1896. doi:10.2146/ajhp130143
   PubMed Web of Science ®Google Scholar
• Wu L, Acon D, Berrocal MH, et al. Five-year outcomes after intravitreal bevacizumab of treatment-naïve eyes with macular edema secondary to CRVO in routine clinical practice: results of the Pan-American Collaborative Retina Study (PACORES) group. Int Ophthalmol. 2022;42(3):951–958. doi:10.1007/s10792-021-02077-5
   PubMed Web of Science ®Google Scholar
• Eldeeb M, Chan EW, Dedhia CJ, Mansour A, Chhablani J. One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion. Am J Ophthalmol Case Rep. 2017;8:58–61. doi:10.1016/j.ajoc.2017.10.011
   PubMedGoogle Scholar
• Mansour AM, Ashraf M, Charbaji A, et al.; Ziv-aflibercept study group investigators. Two-year outcomes of intravitreal ziv-aflibercept. Br J Ophthalmol. 2018;102(10):1387–1390. doi:10.1136/bjophthalmol-2017-311591
   PubMed Web of Science ®Google Scholar
• Braimah IZ, Agyabeng K, Amoaku WM. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series. Int Ophthalmol. 2021;41(7):2445–2453. doi:10.1007/s10792-021-01799-w
   PubMed Web of Science ®Google Scholar
• Paulose R, Chhablani J, Dedhia CJ, Stewart MW, Mansour AM. Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion. Clin Ophthalmol. 2016;10:1853–1858. doi:10.2147/OPTH.S116343
   PubMed Web of Science ®Google Scholar
• Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG; CONSORT Group. Reporting of non-inferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594–2604. doi:10.1001/jama.2012.87802
   PubMed Web of Science ®Google Scholar
• Lin J, Gibbons A, Smiddy WE. Cost-utility of anti-vascular endothelial growth factor treatment for macular edema secondary to central retinal vein occlusion. Ophthalmol Retina. 2021;5(7):656–663. doi:10.1016/j.oret.2020.09.017
   PubMedGoogle Scholar
• Wecker T, Ehlken C, Bühler A, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101(3):353–359. doi:10.1136/bjophthalmol-2016-308668
   PubMed Web of Science ®Google Scholar
• Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophthalmol. 2018;12:621–629. doi:10.2147/OPTH.S163859
   PubMed Web of Science ®Google Scholar
• Singh SR, Stewart MW, Chattannavar G, et al. Safety of 5914 intravitreal ziv-aflibercept injections. Br J Ophthalmol. 2019;103(6):805–810. doi:10.1136/bjophthalmol-2018-312453
   PubMed Web of Science ®Google Scholar
• Chhablani J, Dedhia CJ, Peguda HK, Stewart M. Short-term safety of 2 MG intravitreal ziv-aflibercept. Retina. 2017;37(10):1859–1865. doi:10.1097/IAE.0000000000001440
   PubMed Web of Science ®Google Scholar
• de Oliveira Dias JR, de Andrade GC, Kniggendorf VF, et al. Clinical and electrophysiological evaluation after intravitreal ziv-aflibercept for exudative age-related macular degeneration. Retina. 2017;37(8):1499–1507. doi:10.1097/IAE.0000000000001385
   PubMed Web of Science ®Google Scholar
• de Andrade GC, de Oliveira Dias JR, Maia A, Farah ME, Meyer CH, Rodrigues EB. Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes. Ophthalmic Surg Lasers Imaging Retina. 2018;49(4):245–250. doi:10.3928/23258160-20180329-06
   PubMed Web of Science ®Google Scholar
• de Oliveira Dias JR, Costa de Andrade G, Kniggendorf VF. Intravitreal ziv-aflibercept for neovascular age-related macular degeneration: 52-Week Results. Retina. 2019;39(4):648–655. doi:10.1097/IAE.0000000000002001
   PubMed Web of Science ®Google Scholar